ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma

Sorafenib is the first-line treatment of advanced hepatocellular carcinoma (HCC). However, there is a lack of validated biomarkers to predict sorafenib sensitivity. In this study we investigated the role of ACSL4, a positive-activating enzyme of ferroptosis, in sorafenib-induced cell death and HCC p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Acta Pharmacol Sin
Main Authors: Feng, Ji, Lu, Pei-zhi, Zhu, Guang-zhi, Hooi, Shing Chung, Wu, Yong, Huang, Xiao-wei, Dai, Hui-qi, Chen, Pan-hong, Li, Zhong-jie, Su, Wen-jing, Han, Chuang-ye, Ye, Xin-ping, Peng, Tao, Zhou, Jing, Lu, Guo-dong
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Singapore 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7921679/
https://ncbi.nlm.nih.gov/pubmed/32541921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41401-020-0439-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados